Prevalence of primary non‐alcoholic fatty liver disease in a population‐based study and its association with biochemical and anthropometric measures
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Background/Aims: Only a few studies have assessed the epidemiology of non‐alcoholic fatty liver disease (NAFLD). The aim was to evaluate the prevalence of primary NAFLD in a population‐based study in Israel and to determine independent risk factors. Methods: A cross‐sectional study of a subsample of the Israeli national health survey (n=352). Individuals with a known etiology for secondary NAFLD were excluded. Each participant underwent an abdominal ultrasound, biochemical tests and an anthropometric evaluation. Results: Three hundred and twenty‐six subjects (53.4% male, mean age 50.5±10.3 standard deviaton [SD]) met the inclusion criteria. The prevalence of primary NAFLD was 30% (25–35% 95% confidence intervals [CI]). NAFLD was more prevalent in men than women (38% vs. 21%; P=0.001). Compared with ultrasonography, the sensitivity of serum alanine transaminase (ALT) for the diagnosis of primary NAFLD was 8.2%. Risk factors independently associated with NAFLD included male gender (odds ratios (OR)=2.8, 95% CI 1.5–5.3), abdominal obesity (OR=2.9, 95% CI 1.3–6.4), homeostasis model assessment (OR=5.8, 95% CI 2.0–17.2), hyperinsulinemia (OR=2.3, 95% CI 1.2–4.3, P=0.01) and hypertriglyceridemia (OR=2.4, 95% CI 1.3–4.5). Conclusions: NAFLD is prevalent in the general Israeli population and closely related to the metabolic syndrome. The use of ALT as a marker for NAFLD seriously underestimates its prevalence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. Z. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,295
Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66378-7 · Cited by 5,550
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345 · cited 1×
“Non-alcoholic fatty liver disease (NAFLD) is an increasingly recognized condition that includes a wide spectrum of liver damage, ranging from simple steatosis to advanced fibrosis and cirrhosis (1).”
BackgroundLudwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,679
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581 · cited 1×
“NAFLD is now considered to be the hepatic manifestation of the metabolic syndrome (14, 15), which includes central obesity, hypertension, hypertriglyceridemia, low levels of high-density lipoprotein (HDL) and hyperglycemia (16).”
BackgroundBonora, E., Targher, G., Alberiche, M., Bonadonna, R. C., Saggiani, F., Zenere, M. B., Monauni, T., & Muggeo, M. (2000) · Diabetes Care · doi:10.2337/diacare.23.1.57 · Cited by 2,456
Cited by
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
“Furthermore, the prevalence of NAFLD in men is 2 times higher than in women.((33,34,38)) The issues of ethnicity and its impact on NAFLD have evolved over the years.”
BackgroundVernon, G., Baranova, A., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,074
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease
Cotter, T. G., & Rinella, M. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.052 · Cited by 1,198
A position statement on NAFLD/NASH based on the EASL 2009 special conference
Ratziu, V., Bellentani, S., Cortez-Pinto, H., Day, C., & Marchesini, G. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.04.008 · Cited by 1,058
Lonardo, A., Nascimbeni, F., Ballestri, S., Fairweather, D., Win, S., Than, T. A., Abdelmalek, M. F., & Suzuki, A. (2019) · Hepatology · doi:10.1002/hep.30626 · Cited by 1,050
Pi-Sunyer, X. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.11.2074 · Cited by 1,025
Pi-Sunyer, F. X. (2002) · Obesity Surgery · doi:10.1007/bf03342140 · Cited by 827
Nonalcoholic fatty liver disease
Brunt, E. M., Wong, V. W.-S., Nobili, V., Day, C. P., Sookoian, S., Maher, J. J., Bugianesi, E., Sirlin, C. B., Neuschwander-Tetri, B. A., & Rinella, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.80 · Cited by 818
Ryan, M. C., Itsiopoulos, C., Thodis, T., Ward, G., Trost, N., Hofferberth, S., O’Dea, K., Desmond, P. V., Johnson, N. A., & Wilson, A. M. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.02.012 · Cited by 778
2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis
Le, M. H., Yeo, Y. H., Li, X., Li, J., Zou, B., Wu, Y., Ye, Q., Huang, D. Q., Zhao, C., Zhang, J., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.12.002 · Cited by 711
Noureddin, M., Vipani, A., Bresee, C., Todo, T., Kim, I. K., Alkhouri, N., Setiawan, V. W., Tran, T., Ayoub, W. S., Lu, S. C., et al. (2018) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0088-6 · Cited by 578
Zelber-Sagi, S., Nitzan-Kaluski, D., Goldsmith, R., Webb, M., Blendis, L., Halpern, Z., & Oren, R. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.06.020 · Cited by 551
Self-citationBallestri, S., Nascimbeni, F., Baldelli, E., Marrazzo, A., Romagnoli, D., & Lonardo, A. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0556-1 · Cited by 545
Non-alcoholic fatty liver disease, obesity and the metabolic syndrome
Dietrich, P., & Hellerbrand, C. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.008 · Cited by 457
Mitochondria and Reactive Oxygen Species in Aging and Age-Related Diseases
(2018) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2018.05.006 · Cited by 455
Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups
Lonardo, A., Bellentani, S., Argo, C. K., Ballestri, S., Byrne, C. D., Caldwell, S. H., Cortez-Pinto, H., Grieco, A., Machado, M. V., Miele, L., et al. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.08.004 · Cited by 444
Metabolic syndrome and hepatocellular carcinoma: Two growing epidemics with a potential link
Siegel, A. B., & Zhu, A. X. (2009) · Cancer · doi:10.1002/cncr.24687 · Cited by 399
Obesity-Associated Liver Disease
Marchesini, G., Moscatiello, S., Di Domizio, S., & Forlani, G. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1399 · Cited by 359
Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study
Mizrahi, B., Sudry, T., Flaks-Manov, N., Yehezkelli, Y., Kalkstein, N., Akiva, P., Ekka-Zohar, A., Ben David, S. S., Lerner, U., Bivas-Benita, M., et al. (2023) · BMJ · doi:10.1136/bmj-2022-072529 · Cited by 335
Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-Based Cohort Study
Dunn, W., Xu, R., Wingard, D. L., Rogers, C., Angulo, P., Younossi, Z. M., & Schwimmer, J. B. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.02034.x · Cited by 325
Nutrition and physical activity in NAFLD: An overview of the epidemiological evidence
Zelber-Sagi, S. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i29.3377 · Cited by 300
Self-citationRole of leisure-time physical activity in nonalcoholic fatty liver disease: A population-based study
Zelber-Sagi, S., Nitzan-Kaluski, D., Goldsmith, R., Webb, M., Zvibel, I., Goldiner, I., Blendis, L., Halpern, Z., & Oren, R. (2008) · Hepatology · doi:10.1002/hep.22525 · Cited by 296
Self-citationNon-alcoholic fatty liver disease
Smith, B. W., & Adams, L. A. (2011) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2011.596521 · Cited by 285
Zhang, S., Du, T., Zhang, J., Lu, H., Lin, X., Xie, J., Yang, Y., & Yu, X. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0409-6 · Cited by 284
Non-Alcoholic Fatty Liver Disease in Older People
Frith, J., Day, C. P., Henderson, E., Burt, A. D., & Newton, J. L. (2009) · Gerontology · doi:10.1159/000235677 · Cited by 282
Zelber-Sagi, S., Lotan, R., Shlomai, A., Webb, M., Harrari, G., Buch, A., Nitzan Kaluski, D., Halpern, Z., & Oren, R. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.011 · Cited by 277
Self-citationNonalcoholic fatty liver disease and aging: epidemiology to management.
Bertolotti, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i39.14185 · Cited by 270
Incidence and natural course of fatty liver in the general population: The Dionysos study
Bedogni, G., Miglioli, L., Masutti, F., Castiglione, A., Crocè, L. S., Tiribelli, C., & Bellentani, S. (2007) · Hepatology · doi:10.1002/hep.21827 · Cited by 226
“liver disease (SLD) was operationally defined as 1 or more of the following: (1) ALT 40 U/L; (2) AST 37 U/L; (3) -glutamyltransferase (GGT) 50 U/L; (4) mean corpuscular volume 100 fL; (5) platelets 100 109/L; (6) positivity to anti-HCV antibodies; and (7) positivity to HBV surface antigen.”
BackgroundOrci, L. A., Gariani, K., Oldani, G., Delaune, V., Morel, P., & Toso, C. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.04.036 · Cited by 209
Luci, C., Bourinet, M., Leclère, P. S., Anty, R., & Gual, P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.597648 · Cited by 195
Festi, D., Schiumerini, R., Marzi, L., Di Biase, A. R., Mandolesi, D., Montrone, L., Scaioli, E., Bonato, G., Marchesini‐Reggiani, G., & Colecchia, A. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12186 · Cited by 185
Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations
Sherif, Z. A., Saeed, A., Ghavimi, S., Nouraie, S.-M., Laiyemo, A. O., Brim, H., & Ashktorab, H. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4143-0 · Cited by 179
Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial
Zelber-Sagi, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i15.4382 · Cited by 152
Self-citationLonardo, A., & Suzuki, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051278 · Cited by 129
Metadata
- Authors
- Zelber‐Sagi, S., Nitzan‐Kaluski, D., Halpern, Z., & Oren, R.
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2006-08-03
- Volume
- 26
- Issue
- 7
- Pages
- 856-863
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W1967726960
- Cited by
- 289
- References
- 44
- FWCI
- 9.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.